Two-year sustained weight loss and metabolic benefits with controlled-release Phentermine/Topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Yearbook of Medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0084-3873(12)00321-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010.

  2012cited by this paper
• Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.

  2011cited by this paper
• Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

  2011cited by this paper
• A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.

  2003cited by this paper
• Orlistat for the treatment of obesity: rapid review and cost‐effectiveness model

  2000cited by this paper

• Obesity management for cardiovascular disease prevention

  2023cites this paper
• Pharmacological Support for the Treatment of Obesity—Present and Future

  2023cites this paper
• Pharmacotherapeutic options for the management of obesity in children

  2023cites this paper
• Practical guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN/UEG guideline.

  2023cites this paper
• Albizia julibrissin Exerts Anti-Obesity Effects by Inducing the Browning of 3T3L1 White Adipocytes

  2023cites this paper
• New insights into the treatment of obesity

  2023cites this paper
• Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis

  2023cites this paper
• Pharmacological approaches to the prevention of type 2 diabetes mellitus

  2023cites this paper
• Case report of PLXNA4 variant associated with hyper-response to phentermine/topiramate pharmacotherapy: Potential genetic basis for superior weight loss response?

  2023influential citation
• Pharmacotherapy for Children and adolescents with overweight and obesity: a systematic review and network meta-analysis of randomized controlled trials

  2023cites this paper
• A Narrative Review: Phentermine and Topiramate for the Treatment of Pediatric Obesity

  2023influential citation
• Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies

  2023cites this paper
• Approved Anti-Obesity Medications in 2022 KSSO Guidelines and the Promise of Phase 3 Clinical Trials: Anti-Obesity Drugs in the Sky and on the Horizon

  2023cites this paper
• Impact of a Community-Based Weight Management Program in a North Carolina Health Care System.

  2023cites this paper
• A review of the evidence on cardiovascular outcomes from obesity treatment

  2023cites this paper
• An Updated Approach to Antiobesity Pharmacotherapy: Moving Beyond the 5% Weight Loss Goal

  2023cites this paper
• „Glucagon-like peptide‑1“(GLP‑1)-Rezeptor-Agonisten – die neuen Wunderwaffen in der Adipositastherapie?

  2023cites this paper
• Current and future pharmacotherapies for obesity in children and adolescents

  2023cites this paper
• Obesity Pillars roundtable: Excessive weight reduction with highly effective anti-obesity medications (heAOMs)

  2022cites this paper
• Pharmacologic treatment of obesity

  2022cites this paper
• AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.

  2022cites this paper
• Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022

  2022cites this paper
• Signaling pathways in obesity: mechanisms and therapeutic interventions

  2022cites this paper
• Recent Advances in Anti-Obesity Drugs

  2022cites this paper
• Developing weight navigation program to support personalized and effective obesity management in primary care settings: protocol for a quality improvement program with an embedded single-arm pilot study

  2022cites this paper
• Obesity Treatment in Orthopaedic Surgery

  2022cites this paper
• The role of GLP-1 receptor agonists in managing type 2 diabetes

  2022cites this paper
• A narrative review of anti-obesity medications for obese patients with osteoarthritis

  2022cites this paper
• The role of GLP-1 receptor agonists in managing type 2 diabetes.

  2022cites this paper
• Updating obesity management strategies: an audit of Italian specialists

  2022influential citation
• Research Progress of Slimming Products and Their Pharmacological Mechanisms

  2022cites this paper
• Phentermine–topiramate extended release for the dual treatment of obesity and sleep-related eating disorder: a case report

  2022cites this paper
• Off-label drugs for obesity

  2022cites this paper
• The shades of grey in adipose tissue reprogramming

  2022cites this paper
• The Australian Obesity Management Algorithm: A simple tool to guide the management of obesity in primary care.

  2022cites this paper
• Obesity pillars roundtable: Phentermine – Past, present, and future

  2022cites this paper
• New therapies for obesity

  2022cites this paper
• Benefits of weight loss of 10% or more in patients with overweight or obesity: A review

  2022influential citation
• Nonalcoholic Fatty Liver Disease and Topiramate as an Antiobesity Drug

  2022cites this paper
• Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

  2022cites this paper
• Bariatric surgery during COVID-19 in the UK: a British Obesity and Metabolic Surgery Society (BOMSS) survey

  2021cites this paper
• An update on pharmacotherapeutic strategies for obesity

  2021cites this paper
• Comparing effectiveness of fat burners and thermogenic supplements to diet and exercise for weight loss and cardiometabolic health: Systematic review and meta-analysis

  2021cites this paper
• Anorectic interaction and safety of 5-hydroxytryptophan/carbidopa plus phentermine or diethylpropion in rat

  2021cites this paper
• Simulating the Fiscal Impact of Anti-Obesity Medications as an Obesity Reduction Strategy

  2021cites this paper
• Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta‐Analysis

  2021cites this paper
• New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications

  2021cites this paper
• DMSO_A_223618 2807..2827

  2021cites this paper
• Long‐term weight loss maintenance with obesity pharmacotherapy: A retrospective cohort study

  2021influential citation
• Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases

  2021cites this paper
• Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists

  2021influential citation
• Describing the Weight‐Reduced State: Physiology, Behavior, and Interventions

  2021cites this paper
• Obesity–An Update on the Basic Pathophysiology and Review of Recent Therapeutic Advances

  2021cites this paper
• Pharmacologic Weight Loss: An Underutilized Practice in the Fight Against Obesity

  2021influential citation
• Comprehensive Review of Current and Upcoming Anti-Obesity Drugs

  2020cites this paper
• Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review

  2020cites this paper
• Obesity-Related Changes in High-Density Lipoprotein Metabolism and Function

  2020cites this paper
• Management of chronic diseases in preventive cardiology: Revisiting “the Problem of Obesity.”

  2020cites this paper
• Experimental Studies to Define the Role of Calcium (Ca2+) and Voltage-Gated Calcium Channel Blockers (vCa-CCB) against Neurosteroid Induced Obesity

  2020cites this paper
• A Review of Past and Present Weight Loss Strategies and the Potential Role of Bariatric Arterial Embolization

  2020cites this paper
• CNS-targeting pharmacological interventions for the metabolic syndrome

  2019cites this paper
• Current Treatments on Obesity

  2019cites this paper
• Pharmacologic Randomized Clinical Trials in Prevention of Type 2 Diabetes

  2019cites this paper
• Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects.

  2019cites this paper
• Pharmacotherapy of Obesity: Limits and Perspectives

  2019cites this paper
• Pharmacological Treatment of Obesity

  2019cites this paper
• CNS-targeting pharmacological interventions for the metabolic syndrome.

  2019cites this paper
• Consenso ALAD. Tratamiento del paciente con diabetes mellitus tipo 2 y obesidad

  2019cites this paper
• The safety of pharmacologic treatment for pediatric obesity

  2018cites this paper
• Safety and tolerability of new-generation anti-obesity medications: a narrative review

  2018cites this paper
• Addressing Obesity in Clinical Gynecology Practice

  2018cites this paper
• Lifestyle Changes and Weight Loss: Effects in PCOS

  2018cites this paper
• Updates on obesity pharmacotherapy

  2018cites this paper
• Anorectic efficacy and safety of the diethylpropion‐topiramate combination in rats

  2018cites this paper
• Cardiovascular Safety During and After Use of Phentermine and Topiramate

  2018cites this paper
• A Review of the Neurobiology of Obesity and the Available

  2018cites this paper
• Obesity Pharmacotherapy.

  2018cites this paper
• Observational Comparative Effectiveness of Pharmaceutical Treatments for Obesity within the Veterans Health Administration

  2018cites this paper
• Psychopharmacological advances in eating disorders

  2018cites this paper
• Pharmacotherapy for obesity in individuals with type 2 diabetes

  2018cites this paper
• AACE/ACE Consensus Statement CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM – 2018 EXECUTIVE SUMMARY

  2018cites this paper
• The Science of Obesity Management: An Endocrine Society Scientific Statement.

  2018cites this paper
• The antiepileptics: Drug choice in newly diagnosed epilepsy

  2018cites this paper
• Obesity: A Review of Pathogenesis and Management Strategies in Adult

  2017cites this paper
• Vascular risk in obesity: Facts, misconceptions and the unknown

  2017cites this paper
• Obesity Epidemic: Pharmaceutical Weight Loss.

  2017cites this paper
• A review of the neurobiology of obesity and the available pharmacotherapies

  2017cites this paper
• Proportional Feedback Control of Energy Intake during Obesity Pharmacotherapy

  2017cites this paper
• Pharmacotherapy for obesity.

  2017cites this paper
• Treatment of Obesity in Patients With Diabetes

  2017cites this paper
• Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release

  2017influential citation
• Coadministration of Canagliflozin and Phentermine for Weight Management in Overweight and Obese Individuals Without Diabetes: A Randomized Clinical Trial

  2017cites this paper
• Combination therapy for obesity

  2017cites this paper
• Obesity: Pathogenesis and emerging targets for drug development

  2017influential citation
• The Phantom of Metformin-Induced Lactic Acidosis in End-Stage Renal Disease Patients: Time to Reconsider with Peritoneal Dialysis Treatment

  2017cites this paper
• Exploratory Literature Meta‐Analysis to Characterize the Relationship Between Early and Longer Term Body Weight Loss for Antiobesity Compounds

  2017cites this paper
• control del paciente con diabetes mellitus tipo 2 : hacia una visión adipocéntrica del abordaje de la diabetes

  2017cites this paper
• Obesity Pharmacotherapy in Patients With Type 2 Diabetes

  2017cites this paper
• Pharmacotherapy for obesity: What you need to know

  2017cites this paper
• Obesity management among patients with type 2 diabetes and prediabetes: a focus on lifestyle modifications and evidence of antiobesity medications

  2017cites this paper